Monika E Hegi

发表

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

Walter J Curran, Deborah T Blumenthal, Mark R Gilbert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changing paradigms--an update on the multidisciplinary management of malignant glioma.

Michael Weller, R. Mirimanoff, R. Stupp, 2006, The oncologist.

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Michael Weller, Wolfgang Wick, Guido Reifenberger, 2012, Neuro-oncology.

Retraction Note: Marker-independent identification of glioma-initiating cells

Rolf Gruetter, Ivan Radovanovic, Nicolas de Tribolet, 2013, Nature Methods.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Alessia Pica, Bart Neyns, Michael Weller, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA fingerprinting of glioma cell lines and considerations on similarity measurements.

Mauro Delorenzi, Vincent Castella, M. Delorenzi, 2012, Neuro-oncology.

Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.

Eytan Domany, Gad Getz, Mauro Delorenzi, 2003, Cancer research.

Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma

Eytan Domany, Mauro Delorenzi, Michael Weller, 2015, Genome Biology.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Didier Frappaz, R. Stupp, C. Marosi, 2012, The Lancet. Oncology.

p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma

Erwin G. Van Meir, R. Janzer, G. Fulci, 2000, Oncogene.

Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.

Mauro Delorenzi, M. Delorenzi, M. Hegi, 2016, The Journal of molecular diagnostics : JMD.

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

Elizabeth Eisenhauer, Denis Lacombe, Michael Weller, 2008, The Lancet. Oncology.

Chemoradiotherapy in malignant glioma: standard of care and future directions.

Mark R Gilbert, Arnab Chakravarti, M. Gilbert, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.